Lysogene Receives Orphan Drug Designation from FDA for LYS-GM101
Lysogene announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to LYS-GM101, the company’s gene therapy drug candidate for treatment of GM1…
Read More...
Read More...